MeiraGTx Holdings plc
MGTX
Positions held
Your positionsMGTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- MeiraGTx Holdings is positioned in a rapidly advancing biotechnology sector, focusing on innovative gene therapies that address significant unmet medical needs.
- In Q2 2026, MeiraGTx reported a revenue of $321.434 million, a staggering increase of 109,604% compared to the previous quarter.
- The company achieved a gross margin of 97.8% in Q2 2026, significantly up from 32.4% in Q1 2026.
- Despite its potential, MeiraGTx faces intense competition in the biotechnology space, which can impact its market share and pricing strategies.
- The company's operating margin was negative at -13930.72% in Q1 2026, indicating severe operational challenges.
- MeiraGTx has a current score of 'Strong Sell' with a score of -16.00, reflecting negative market sentiment and technical indicators.
Fundamentals
| Market cap | $1.01B | Enterprise value | $977.82M | Trailing P/E | 12.07 | Forward P/E | -6.89 |
| PEG | — | Price / book | 4.59 | Beta | 1.35 | Dividend yield | 0.00% |
| Revenue growth | 86.1% | Earnings growth | — | Gross margin | 97.9% | Operating margin | 76.0% |
| Profit margin | 19.9% | ROE | 72.2% | ROA | 38.7% | Debt / equity | 0.52 |
| Current ratio | 3.76 | Free cash flow | $56.42M | Analyst recommendation | strong_buy | Mean target | $27.75 |
| 52w high | $15.35 | 52w low | $6.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $321M | $0.3M | $75.4M | $0.4M | $3.7M | — |
| Op margin | 76.0% | -13930.7% | 35.1% | -11232.0% | -1213.6% | — |
| Net income | $161M | -$46.3M | $15.1M | -$50.5M | -$38.8M | — |
| Gross margin | 97.8% | 32.4% | 99.4% | 23.7% | 27.5% | — |
| Gross profit | $314M | $0.1M | $74.9M | $0.1M | $1.0M | — |
| Operating income | $244M | -$40.8M | $26.5M | -$46.1M | -$44.8M | — |
- Revenue +109604% vs prior quarter ($321M vs $0.3M).
- Gross margin 97.8% (was 32.4% prior quarter).
- Operating margin expanded to 76%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $81.4M | $33.3M | $14.0M | $15.9M | — |
| Op margin | -130.2% | -493.4% | -977.8% | -730.9% | — |
| Net income | -$114M | -$148M | -$84.0M | -$130M | — |
| Gross margin | 94.0% | 28.5% | 100.0% | — | — |
| Gross profit | $76.5M | $9.5M | $14.0M | — | — |
| Operating income | -$106M | -$164M | -$137M | -$116M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-24 · Goldman Sachs Initiates MeiraGTx at Neutral With $16 Price Target
2026-09-23 · MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
2026-08-14 · What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?
2026-08-14 · MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says
2026-08-14 · RBC Adjusts PT on MeiraGTx to $27 From $26, Maintains Outperform Speculative Risk Rating
2026-08-13 · Sector Update: Healthcare Stocks Softer in Afternoon Trading
2026-08-13 · MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
2026-08-13 · Sector Update: Healthcare Stocks Advance Pre-Bell Thursday
2026-08-13 · Sector Update: Healthcare
2026-08-13 · MeiraGTx Swings to Q2 Profit, Revenue Rises
2026-08-13 · MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Price (daily)
Full chart · RSI · MACD · patterns